Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The AML-03 regimen investigates the addition of G-CSF priming to both induction and
consolidation chemotherapies administrated in the previous AML-99 trial (NCT01716793) refines
risk-stratification based on biological characterization also the AML-03 trial incorporates
novel approaches for hematopoietic stem cell transplantation: such as Mylotarg™ "in vivo
purging" in autografts, extends unrelated volunteers donors for allotransplants in high-risk
patients, and introduces reduced intensity conditioning in patients with elder age (more than
50 years old).
The aims of these modifications are to analyse eficacy and toxicity of this induction and
consolidation therapy and to analyse the disease free survival in patients who achieved
complete response following a risk adjusted therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias